Uncontrolled inflammation underpins a diverse range of diseases where effective therapy remains an unmet clinical need. Hypoxia is a prominent feature of the inflammatory microenvironment that regulates key transcription factors including HIF and NF-κB in both innate and adaptive immune cells. In turn, altered activity of the pathways controlled by these factors can affect the course of inflammation through the regulation of immune cell development and function. In this review, we will discuss these pathways and the oxygen sensors that confer hypoxic sensitivity in immune cells. Furthermore, we will describe how hypoxia-dependent pathways contribute to immunity and discuss their potential as therapeutic targets in inflammatory and infectious disease.
Hypoxia-dependent regulation of inflammatory pathways in immune cells

Cormac T. Taylor,1,2,3 Glen Doherty,1,4 Padraic G. Fallon,5 and Eoin P. Cummins1

1School of Medicine and Medical Science and the Conway Institute, University College Dublin, Belfield, Dublin, Ireland. 2IRCAN, Centre A. Lacassagne, University of Nice-Sophia Antipolis, Nice, France. 3Centre Scientifique de Monaco (CSM), Monaco. 4Centre for Colorectal Disease, St. Vincent’s University Hospital, Elm Park, Dublin, Ireland. 5Trinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland.

Uncontrolled inflammation underpins a diverse range of diseases where effective therapy remains an unmet clinical need. Hypoxia is a prominent feature of the inflammatory microenvironment that regulates key transcription factors including HIF and NF-κB in both innate and adaptive immune cells. In turn, altered activity of the pathways controlled by these factors can affect the course of inflammation through the regulation of immune cell development and function. In this review, we will discuss these pathways and the oxygen sensors that confer hypoxic sensitivity in immune cells. Furthermore, we will describe how hypoxia-dependent pathways contribute to immunity and discuss their potential as therapeutic targets in inflammatory and infectious disease.

The relationship between hypoxia and inflammation

The appearance and accumulation of gaseous molecular oxygen (O2) in the Earth’s atmosphere approximately 2.3 billion years ago, which occurred as a result of the expansion of oceanic photosynthetic cyanobacteria, resulted in near eradication of the planet’s biomass due to its highly reactive chemistry (1). However, a subset of unicellular organisms, which evolved following the incorporation of mitochondria during an early symbiotic event, developed the ability to withstand the toxic effects of oxygen (2). In fact, these primitive organisms adapted to an oxygen-rich environment by developing the capacity to utilize oxygen’s inherent chemical energy to increase their metabolic potential. This played a major role in providing the capacity for satisfying the bioenergetic demands required for the subsequent evolution of eukaryotic metazoan life on Earth (2, 3). Of note, in early unicellular organisms, the processes of metabolism and primitive immunity shared many common features such as phagocytosis and proteolysis, and therefore there exists an ancient and intimate relationship between these two fundamental processes (4).

O2 plays a vital role in eukaryotic metabolism as the terminal electron acceptor of the mitochondrial electron transport chain, which is responsible for generating the majority of ATP produced by a cell (5). Indeed, eukaryotic cells have developed a strong degree of dependence upon the availability of sufficient levels of O2 to maintain biological activity and remain viable.

Hypoxia occurs when oxygen demand exceeds supply, and as such represents a significant threat to bioenergetic homeostasis and cell survival. A number of recent studies have demonstrated that the microenvironment at sites of inflammation often becomes profoundly hypoxic. Inflammatory pathways in which tissue hypoxia has been documented include atherosclerosis, rheumatoid arthritis, obesity, infection, ischemic disease, cancer, and inflammatory bowel disease (6). The occurrence of hypoxia at sites of inflammation is due to a combination of increased oxygen demand and decreased supply. Oxygen consumption is elevated at inflammatory sites due to the high metabolic demand associated with active inflammation, which is necessary to sustain the synthesis of inflammatory mediators, enzymes, and cytokines (6, 7). In addition, infiltrating neutrophils at sites of inflammation contribute to hypoxia, as these cells require high levels of oxygen to support the oxidative burst that is used as an endogenous antimicrobial strategy (8, 9). Reduced oxygenation of inflamed tissues is of particular relevance in chronic inflammatory diseases of the intestine, such as inflammatory bowel disease, where the development of thrombosis, fibrosis, and associated vascular dysfunction often leads to diminished tissue perfusion (10, 11). Therefore, hypoxia is a common feature of the microenvironment of chronically inflamed tissues.

It has recently become clear that, rather than simply being a consequence of inflammation, hypoxia can actively affect inflammatory processes through the regulation of oxygen-sensitive signaling pathways in multiple immune cell subtypes that are either resident within the inflamed tissue or have migrated from the oxygen-rich bloodstream to the hypoxic inflammatory milieu (6, 12). In this review, we will discuss these pathways and the implications of their activation for the regulation of immunity and inflammation.

Hypoxia-responsive pathways in inflammation

Cellular responses to hypoxia are governed by a marked change in the cellular transcriptome (13). Pan-transcriptomic analyses have identified hundreds of hypoxia-responsive genes, with equivalent numbers of genes having increased or decreased expression levels (14, 15). Over 15 distinct transcription factors display sensitivity to...
Hypoxia and immunity

Hypoxia and inflammation

HIF and immunity

Recently, a major role for HIF has emerged in multiple aspects of immune cell function and survival (Figure 1). This is perhaps unsurprising considering that many immune cells leave the oxygen-rich vasculature as they migrate to hypoxic sites of inflammation. While HIF-1 appears to be expressed in all immune cell types, HIF-2 is more selectively expressed in cells such as neutrophils, NK cells, tumor-associated macrophages, and activated T cells. HIFs are also involved in the regulation of metabolic processes, which can affect the fate and function of immune cells. For example, HIF-1α and HIF-2α are involved in the regulation of glycolytic gene expression and the repression of oxidative phosphorylation (23). Dysregulation of metabolic enzymes involved in the production of these intermediates is associated with altered HIF-dependent signaling (24, 25). In the context of infection, LPS-dependent activation of macrophages leads to metabolic reprogramming, succinate release, and elevated IL-1β production downstream of HIF (26). Therefore, HIF sits in a prime position to link metabolic and immune/inflammatory processes.
phosphorylation for ATP production (28). Not surprisingly, both HIF-1 and HIF-2 play important regulatory functional roles in the control of motility, bactericidal activity, and tumorigenic potential in macrophages (29–31). However, it remains unclear exactly how HIF-1 and HIF-2 participate in the skewing of macrophages towards an M1 or M2 phenotype (20, 22). While HIF-1-dependent glycolysis favors polarization to an M1 phenotype, recent work has indicated that M2 polarization is independent of either HIF isoform, at least in a model of sterile tissue damage (32). Therefore, while it is likely that HIF activation contributes to macrophage polarization, the specific roles of individual HIF isoforms require further investigation.

In neutrophils, HIF-1 and HIF-2 are critical in the control of cell survival and apoptosis. HIF-1 promotes neutrophil survival and bactericidal activity (33, 34). Similarly, HIF-2 appears to support neutrophilic inflammation through the promotion of cell survival (35). Of interest, HIF-2 expression in neutrophils is elevated in patients with inflammatory disease (35). Therefore, in the context of inflammation, HIF-1/2 activation in neutrophils can be considered to be largely proinflammatory.

In dendritic cells (DCs), HIF-1 has been shown to promote cell survival, interferon synthesis, differentiation, and migration (36–38). Furthermore, recent studies have suggested a role for HIF-1α in determining the antigen-presenting function of DCs. Additionally, HIF-1 has been implicated in promoting Treg expansion while limiting the expansion of CD8+ T cells (39, 40). These latter studies support a predominantly antiinflammatory function for HIF-1 in DCs. Little is known about the expression or function of HIF-2 in DCs. In NK cells, HIF-2 limits cellular cytotoxicity, indicating an antiinflammatory role (41). Therefore, HIFs play a key role in multiple aspects of innate immune cell development and function.

**HIF in innate immunity**

Macrophages can differentiate into M1 or M2 phenotypes, which are associated with first-line (proinflammatory) antibacterial defense and wound healing (antiinflammatory) respectively. Additionally, these macrophage phenotypes employ distinct metabolic strategies. M1 macrophages are largely reliant on glycolysis, while M2 macrophages are largely reliant on oxidative
HIF in adaptive immunity

The important role that HIF plays in the regulation of the adaptive immune response and the implications of this regulation for inflammation and cancer have been recently reviewed (21, 22). Depending on environmental cues, CD4+ T cells can differentiate into Tregs, Th1, Th2, or Th17 cells, which have distinct immunological functions. HIF-1 has been reported to regulate T cell survival, proliferation, and differentiation (47). HIF-1 activation promotes a metabolic shift to glycolysis as well as altered transcriptional responses in differentiating T cells (via regulation of the nuclear hormone receptor RORγt and the transcriptional regulator FOXP3), creating an environment favorable for the differentiation to Th17 cells rather than Tregs (21, 48). In activated T cells, HIF-1 promotes cytolysis, migratory, and co-stimulatory properties (22, 49), although HIF-1 has recently been reported to negatively regulate Th1 cell function in some conditions (50). The impact of HIF-1 in Treg function is less clear. One study reports that HIF-1-driven FOXP3 is required for Treg function and cells lacking HIF-1α have reduced antiinflammatory capacity and lose their ability to control inflammation (51). A separate study demonstrated that VHL depletion in Tregs leads to HIF-1 activation, which drives their transformation to Th1 effector killer cells, thereby promoting inflammation (52). In summary, HIF-1 plays a key role in T cell differentiation by promoting glycolytic metabolism and directing key aspects of T cell function, and as such is a key mediator of adaptive T cell–mediated immunity.

In terms of B cell biology, HIF-1α−/− Rag2−/− chimeric mice display B cell lineage defects, including abnormal B1-like lymphocytes and evidence of autoimmunity (53). More recently, HIF-1α has been shown to be important for the expression of TASK-2 potassium channels in B cells. These channels are vital for a number of cellular functions including proliferation, survival, and cytokine production (54). Furthermore, HIF-1α is critical for crosstalk between mature B cells (plasma cells) and the microenvironment in tumors (55). Finally, depletion of HIF-1β leads to alterations in homeostasis and hematopoietic stem cell viability (56). Therefore, in the context of adaptive immune cell activity, HIFs play a key role, which appears to be predominantly antiinflammatory for T cells and prosurvival for B cells.

The studies discussed above provide strong evidence that HIF-1 plays a complex and pleiotropic role in cells of the immune system. A consistent observation throughout these studies is that the effect of genetic HIF depletion from both innate and adaptive immune cell types markedly alters multiple aspects of their function. The discrete and common roles of HIF-1α and HIF-2α in the differentiation and function of certain immune cell subtypes are summarized in Figure 1. The conclusion from the studies outlined above is that the HIF pathway should be considered an important regulator of both innate and adaptive immune cell function and the inflammatory processes that are activated during inflammation.

NF-κB. NF-κB is a hypoxia-sensitive transcription factor that plays an important role in the control of the inflammatory response (57). The NF-κB signaling pathway consists of distinct canonical and noncanonical branches that play a complex and pleiotropic role in the control of inflammation and can regulate both pro- and antiinflammatory processes, depending upon the context. The canonical (but not the noncanonical) branch of the NF-κB pathway has been demonstrated to respond to hypoxia (58). NF-κB serves as a master regulator of the immune response through the regulation of key aspects of immune cell function in macrophages, epithelial cells, neutrophils, DCs, T cells, and B cells. The potent role of NF-κB in the regulation of immunity and inflammation has been extensively reviewed elsewhere and will not be covered in detail here (59). For the purpose of this review, we will focus on our evolving understanding of the mechanistic link between hypoxia and NF-κB activity.

As will be discussed in more detail below, the same hydroxylases responsible for conferring oxygen dependence upon the HIF pathway also regulate hypoxia-dependent NF-κB activity (60), although the exact mechanisms by which this occurs remain to be fully elucidated. Of interest, a number of hydroxylation sites have been identified on components of the NF-κB pathway, supporting a possible role for functional, oxygen-dependent hydroxylation outside of the HIF pathway (Figure 2; refs. 60–64). While hypoxia or pharmacological hydroxylase inhibition causes a moderate increase in basal NF-κB activity in several cell types, it suppresses the activation of NF-κB activity in cells following treatment with cytokines such as IL-1β or bacterial products such as LPS. These effects reflect a complex regulatory role for hypoxia in relation to the NF-κB pathway (65, 66). However, it is now clear that along with HIF, NF-κB is a second hypoxia-responsive transcription
factor that plays a key role in the regulation of inflammation and immunity through its prominent role in the control of immune cell function. Whether NF-κB induces a pro- or anti-inflammatory response depends on the cell type and the degree and duration of its activity in the context of a specific inflammatory lesion.

While both HIF and NF-κB play distinct roles in terms of regulating inflammatory processes, the two pathways have also been shown to display a significant degree of interdependence (67–70). For example, HIF transcription can be upregulated by NF-κB through its binding to a response element present in the HIFIA promoter (71–74); thus, NF-κB activation may serve to amplify the HIF response under conditions of hypoxic inflammation. Conversely, in neutrophils, HIF has been demonstrated to regulate NF-κB activity, although this appears to be a more cell type–specific role, as HIIF-dependent NF-κB activity has not been reported in other cell types (33).

In summary, HIF and NF-κB are two interdependent hypoxia-responsive transcription factors that play a vital role in the control of immune cell function and perform an important bridging role between the microenvironment, metabolism, and the control of immune cell function. Importantly, a common feature of HIF and NF-κB is their regulation by oxygen-sensing hydroxylases, thus identifying these oxygen sensors as potentially important therapeutic targets in inflammatory disease.

Regulation of immune cell function by PHDs
The identification of hydroxylases as the sensors underpinning oxygen dependence of the HIF pathway was first reported in 2001 (75, 76). These studies demonstrated that oxygen-dependent proline hydroxylation of HIF by a family of hydroxylases led to its ubiquitination by the pVHL ubiquitin ligase and subsequent proteasomal degradation in normoxia (18). Another study identified FIH as a second, oxygen-dependent hydroxylase that targets HIF (77, 78). Subsequent studies demonstrated that while HIF is clearly the major pathway regulated by hydroxylation, signaling components of other pathways such as NF-κB are also subject to enzymatic hydroxylation, although the functional consequences of hydroxylation for non-HIF targets remains an area under investigation (62–64, 79).

Because of the role of hydroxylases in the regulation of hypoxia-responsive transcription factors, these enzymes also play a key role in the regulation of immune cell activity (27). While our understanding of the role of HIF hydroxylases in the regulation of immune cell function is far from complete, recent studies investigating individual HIF hydroxylase isoforms in discrete immune and epithelial cell subtypes have identified isoform-specific roles (80–89). Notably, these phenotypes are not fully accounted for by downstream HIF-dependent effects, further supporting the existence of alternative hydroxylation-regulated pathways such as NF-κB in immune cells.

In macrophages, PHD2 loss or haplodeficiency alters M1/M2 cell differentiation in an NF-κB-dependent manner (80, 81), whereas PHD3 loss alters apoptosis and proinflammatory activity (82, 83). In neutrophils, PHD3 regulates apoptosis, although this effect appears to be NF-κB independent (84). In intestinal epithelial cells, PHD1 and PHD3 have been linked with the regulation of apoptosis and tight-junction integrity, respectively (85, 86). Interestingly, the expression of these enzymes was reported to be altered in inflammatory bowel disease, where the intestinal barrier is significantly perturbed (85–87). In keratinocytes, loss of PHD2 alters cell migration and subsequent wound healing in a HIF-dependent manner (88). In lymphocytes, loss of PHD2 is associated with altered cytokine production and immune activity (89). Therefore, multiple studies support a key role for hydroxylases and their downstream targets in the regulation of immunity and inflammation.

Hydroxylase-independent pathways activated in hypoxia
It is worth noting that in addition to HIF and NF-κB, a number of other important hypoxia-sensitive regulators of inflammation are also activated at sites of inflammation, independent of altered hydroxylase activity, and are likely contributors to control of the overall inflammatory state. These regulators do not directly sense changes in oxygen but are sensitive to the sequela downstream of hypoxia-dependent changes in glucose transport, ATP availability, acidosis, oxidative stress, or altered levels of metabolic intermediates. Some examples are given below.

AMPK is a metabolic sensor that is activated in response to ATP depletion that occurs as a result of the metabolic crisis caused by hypoxia, and has recently emerged as a key regulator of inflammatory cell activity (90). The glucocorticoid receptor (GR), which plays a key role in the activation of antiinflammatory genes and the suppression of proinflammatory genes, is activated in response to hypoxia and likely contributes to the overall control of inflammation, although the mechanisms underpinning the activation of the GR by hypoxia remain unclear (91, 92). Members of the cAMP response element–binding protein (CREB) family, including CREB and ATF4, have been shown to be regulated by hypoxia and can in turn regulate the expression of inflammatory genes in immune cells (93, 94). The mTOR pathway, which is activated in response to hypoxia, likely plays a key role in immune cell activity during inflammation (95). Acidosis, which is a feature of the inflammatory microenvironment, is a known regulator of the hypoxic response (96) Indeed, lactate, which is produced during anaerobic respiration, has recently been reported to induce a hypoxic response independent of HIF, via MYC downstream-regulated gene 2 (NDRG2) and Raf/ERK signaling (97).

Therefore, multiple hypoxia-sensitive but hydroxylase-independent pathways in addition to HIF and NF-κB likely contribute to the complex and multifaceted effects of hypoxia on immune cell activity during active inflammation. The complexity of these interactions make the crosstalk between hypoxia and inflammatory pathways an attractive topic for developing a systems biology approach to advance our understanding of the temporal and dynamic aspects of this relationship (98).

Intermittent hypoxia and inflammation
Most studies into hypoxia-dependent transcription have utilized models of continuous or sustained hypoxia, whereas in vivo it is likely that cells experience bouts of fluctuating hypoxia and reoxygenation, as oxygen consumption and delivery is a highly dynamic process both in health and disease. In a number of conditions (exemplified by obstructive sleep apnea syndrome, of which sys-
temic inflammation is a feature), cells clearly experience a more intermittent profile of hypoxia and reoxygenation (99). Indeed, it is likely that other hypoxic pathologies including chronic inflammation and cancer also involve exposure to an intermittent rather than a sustained pattern of hypoxia. Intermittent hypoxia represents a significantly different physiological stimulus than sustained hypoxia, as it also involves repeated exposure to bouts of reoxygenation and associated oxidative stress. Studies into the impact of intermittent hypoxia on cellular signaling pathways have implicated both HIF and NF-κB pathways in response to intermittent hypoxia, although sustained hypoxia favors activation of the HIF pathway while intermittent hypoxia is more selective for the activation of NF-κB-driven inflammation, likely as a result of oxidative stress (99–102). Little is known about the differential effects of intermittent and sustained hypoxia on immune cell function, although this is likely of importance for a full understanding of the impact of physiologically relevant patterns of hypoxia on inflammation and immunity.

Preclinical studies of hydroxylase inhibitors

The evidence outlined above, which supports key roles for hypoxia- and hydroxylase-sensitive transcriptional pathways in immunity and inflammation, indicates that pharmacological interference with these pathways would likely have immunological consequences. However, given the complex and pleiotropic roles of hypoxia-responsive pathways in distinct immune cell types, a prediction of whether hypoxia and/or hydroxylase inhibition would ultimately be pro- or antiinflammatory is difficult to make without testing the impact of pharmacological hydroxylase inhibition in vivo.

Studies implicating hypoxia-responsive pathways in inflammatory disease are supported by data demonstrating the impact of targeting the HIF pathway with pharmacological hydroxylase inhibitors for the treatment of inflammatory disease (12, 103). Initial work in this area demonstrated a beneficial effect of hydroxylase inhibition on disease progression in mouse models of colitis (104, 105). This protective effect was found to be due primarily to the promotion of intestinal epithelial barrier function through the inhibition of apoptosis and the expression of genes that enhance barrier function (46, 106). Subsequent studies demonstrated a broader antiinflammatory effect of pharmacological hydroxylase inhibition in diseases such as ischemic acute kidney injury and sepsis, leading to the conclusion that other mechanisms of therapeutic action may also be involved (65, 107). Indeed, recent studies have implicated hydroxylase inhibitors in the suppression of cytokine-activated NF-κB-dependent proinflammatory pathways, which may underpin a more general antiinflammatory effect of these drugs (64). Therefore, while hypoxia-sensitive pathways clearly play a complex and multifaceted role in the regulation of immunity and inflammation, the pharmacological activation of these pathways through the application of hydroxylase inhibitors provides a strong, net antiinflammatory effect in multiple models (Figure 3). Future clinical studies are likely to be directed towards investigating the potential of hydroxylase inhibitors as a new class of antiinflammatory agents.

In addition to reported antiinflammatory effects, pharmacological hydroxylase inhibition has been shown to ameliorate symptoms associated with infectious disease (108). For example, mice treated with the PHD inhibitor dimethyloxalylglycine, N-(me-thoxyoxoacetyl)-glycine methyl ester (DMOG) are protected in a murine model of respiratory infection with the gram-negative opportunistic pathogen Pseudomonas aeruginosa (109). Consistent with these findings, loss of HIF-1α in mice increases susceptibility to P. aeruginosa-mediated keratitis (110). In other models of infection including Clostridium, Streptococcus, Staphylococcus, and Acinetobacter species, HIF has also been largely found to be protective against pathogens (111–115). Given the evolving issue of antimicrobial resistance in multiple pathogens, future studies will undoubtedly expand on the fascinating potential of targeting host oxygen-sensing pathways for the purpose of regulating host immune in infectious disease.

Clinical potential of hydroxylase inhibitors

Hydroxylase inhibitors have recently been entered into clinical trials for the promotion of erythropoiesis in models of chronic kidney disease–associated anemia (116–118). In these studies, the delivery of systemic doses of hydroxylase inhibitors was well tolerated by patients, paving the way for the possible use of these reagents for the treatment of inflammatory disorders and/or infectious disease. Notably, while systemic exposure of a patient to a hydroxylase inhibitor would be beneficial in anemia in order to promote erythropoiesis, the local delivery of these drugs would be desirable in the treatment of tissue-specific inflammation in order to avoid unwanted systemic effects such as erythropoiesis. Such a targeted delivery–based approach has recently been demonstrated in a murine model of colitis, in which localized delivery of the hydroxylase inhibitor DMOG to the colon using an emulsion-based drug delivery system provided tissue protection at lower doses than the doses needed for systemic delivery and without associated systemic erythropoiesis (119). Mechanisms for targeted colonic delivery (e.g., Multi Matrix System [MMX]) of antiinflammatory agents such as aminosalicylates (5ASA) and budesonide are already used in the clinical care of the inflammatory disorder ulcerative colitis (120, 121). These studies provide proof of concept for the treatment of intestinal inflammation based on local release formulations to maximize drug concentrations in diseased tissue while limiting any potential systemic side effects.

Perspectives

Since the identification of HIF as a ubiquitous regulator of the cellular transcriptional response to hypoxia and the subsequent identification of hydroxylases as the key oxygen sensors in this pathway, our appreciation of the role of hypoxia as a driver of immunity and inflammation has expanded exponentially. The therapeutic payoff for a quarter of a century of basic research in this field is reflected by the recent entry to the clinic of hydroxylase inhibitors for the treatment of anemia. The potential for repurposing these drugs for inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, and ischemia is a real possibility in the near future.

Some key aspects of the biology of hypoxia-dependent pathways in inflammation require further investigation. These include extensive characterization of the safety and side effects of systemically administered hydroxylase inhibitors and the possibility of developing more targeted, tissue-specific delivery systems.
The differential roles of HIF-1– and HIF-2–dependent activity in immune cell subpopulations in both resting and activated states requires further investigation, particularly using comparative studies. Furthermore, the association between hypoxia and other key aspects of the inflammatory microenvironment such as the prevailing cytokine/chemokine milieu and altered carbon dioxide levels and associated changes in pH need to be considered (122, 123). Finally, comparative studies of intermittent versus sustained patterns of hypoxia in immune cells will strengthen our understanding of the role of physiologically relevant patterns of hypoxia exposure during inflammation. The near future will provide us with these and other exciting new insights into the ancient association between hypoxia, metabolism, and immunity, which will lead to the development of new therapeutic opportunities for inflammatory and infectious disease.

Acknowledgments

The authors work is supported by grants from Science Foundation Ireland, the European Union, and financial support from the University College Dublin School of Medicine.

Address correspondence to: Cormac T. Taylor, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland. Phone: 353.1.716.6732; E-mail: Cormac.taylor@ucd.ie.

7. Lalonde C, Demling RH, Goad ME. Tissue hypoxic exposure during inflammation. The near future will provide us with these and other exciting new insights into the ancient association between hypoxia, metabolism, and immunity, which will lead to the development of new therapeutic opportunities for inflammatory and infectious disease.

Acknowledgments

The authors work is supported by grants from Science Foundation Ireland, the European Union, and financial support from the University College Dublin School of Medicine.

Address correspondence to: Cormac T. Taylor, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland. Phone: 353.1.716.6732; E-mail: Cormac.taylor@ucd.ie.

7. Lalonde C, Demling RH, Goad ME. Tissue hypoxic exposure during inflammation. The near future will provide us with these and other exciting new insights into the ancient association between hypoxia, metabolism, and immunity, which will lead to the development of new therapeutic opportunities for inflammatory and infectious disease.

Acknowledgments

The authors work is supported by grants from Science Foundation Ireland, the European Union, and financial support from the University College Dublin School of Medicine.

Address correspondence to: Cormac T. Taylor, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland. Phone: 353.1.716.6732; E-mail: Cormac.taylor@ucd.ie.


